Prelude Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-463
| Closed | -$210K | – | 1620 |
|
|
2025
Q4 | $210K | Buy |
+463
| New | +$200K | 0.02% | 1033 |
|
|
2025
Q2 | – | Sell |
-5,632
| Closed | -$2.73M | – | 1389 |
|
|
2025
Q1 | $2.73M | Sell |
5,632
-30
| -0.5% | -$14K | 0.21% | 98 |
|
|
2024
Q4 | $2.28M | Sell |
5,662
-243
| -4% | -$113K | 0.14% | 158 |
|
|
2024
Q3 | $2.75M | Buy |
5,905
+29
| +0.5% | +$13.9K | 0.17% | 156 |
|
|
2024
Q2 | $2.75M | Buy |
5,876
+104
| +2% | +$45.1K | 0.19% | 141 |
|
|
2024
Q1 | $2.41M | Sell |
5,772
-1,081
| -16% | -$457K | 0.13% | 199 |
|
|
2023
Q4 | $2.79M | Buy |
6,853
+872
| +15% | +$322K | 0.18% | 121 |
|
|
2023
Q3 | $2.08M | Sell |
5,981
-577
| -9% | -$202K | 0.14% | 182 |
|
|
2023
Q2 | $2.31M | Buy |
6,558
+5,713
| +676% | +$1.92M | 0.15% | 170 |
|
|
2023
Q1 | $266K | Sell |
845
-489
| -37% | -$147K | 0.02% | 697 |
|
|
2022
Q4 | $385K | Buy |
+1,334
| New | +$407K | 0.02% | 685 |
|
|
2022
Q2 | – | Sell |
-6,587
| Closed | -$1.72M | – | 2085 |
|
|
2022
Q1 | $1.72M | Buy |
6,587
+3,237
| +97% | +$768K | 0.05% | 401 |
|
|
2021
Q4 | $736K | Buy |
3,350
+1,096
| +49% | +$213K | 0.02% | 787 |
|
|
2021
Q3 | $409K | Buy |
+2,254
| New | +$440K | 0.01% | 1002 |
|
|
2020
Q2 | – | Sell |
-3,204
| Closed | -$869K | – | 2282 |
|
|
2020
Q1 | $762K | Sell |
3,204
-1,566
| -33% | -$359K | 0.05% | 254 |
|
|
2019
Q4 | $1.04M | Sell |
4,770
-3,076
| -39% | -$623K | 0.04% | 376 |
|
|
2019
Q3 | $1.33M | Buy |
7,846
+6,533
| +498% | +$1.16M | 0.06% | 263 |
|
|
2019
Q2 | $241K | Sell |
1,313
-3,007
| -70% | -$526K | 0.01% | 678 |
|
|
2019
Q1 | $795K | Buy |
4,320
+3,714
| +613% | +$686K | 0.04% | 385 |
|
|
2018
Q4 | $100K | Sell |
606
-9,464
| -94% | -$1.64M | 0.01% | 933 |
|
|
2018
Q3 | $1.94M | Sell |
10,070
-21,858
| -68% | -$3.89M | 0.11% | 203 |
|
|
2018
Q2 | $5.43M | Buy |
31,928
+13,662
| +75% | +$2.12M | 0.34% | 47 |
|
|
2018
Q1 | $2.98M | Sell |
18,266
-5,499
| -23% | -$898K | 0.22% | 74 |
|
|
2017
Q4 | $3.56M | Buy |
23,765
+4,010
| +20% | +$594K | 0.29% | 67 |
|
|
2017
Q3 | $3M | Buy |
19,755
+4,461
| +29% | +$671K | 0.27% | 77 |
|
|
2017
Q2 | $1.97M | Buy |
15,294
+8,225
| +116% | +$990K | 0.19% | 119 |
|
|
2017
Q1 | $773K | Buy |
+7,069
| New | +$622K | 0.07% | 269 |
|
|
2016
Q4 | – | Sell |
-2,331
| Closed | -$190K | – | 1798 |
|
|
2016
Q3 | $203K | Buy |
+2,331
| New | +$220K | 0.02% | 559 |
|
|
2016
Q2 | – | Sell |
-1,779
| Closed | -$141K | – | 1767 |
|
|
2016
Q1 | $141K | Sell |
1,779
-5,209
| -75% | -$471K | 0.02% | 654 |
|
|
2015
Q4 | $879K | Buy |
6,988
+1,105
| +19% | +$133K | 0.14% | 177 |
|
|
2015
Q3 | $613K | Sell |
5,883
-202
| -3% | -$26K | 0.09% | 241 |
|
|
2015
Q2 | $751K | Sell |
6,085
-730
| -11% | -$92K | 0.11% | 224 |
|
|
2015
Q1 | $804K | Buy |
6,815
+4,080
| +149% | +$489K | 0.11% | 226 |
|
|
2014
Q4 | $325K | Sell |
2,735
-2,049
| -43% | -$231K | 0.05% | 471 |
|
|
2014
Q3 | $537K | Buy |
4,784
+795
| +20% | +$75.7K | 0.08% | 337 |
|
|
2014
Q2 | $378K | Sell |
3,989
-3,869
| -49% | -$271K | 0.05% | 484 |
|
|
2014
Q1 | $556K | Buy |
7,858
+4,613
| +142% | +$365K | 0.07% | 357 |
|
|
2013
Q4 | $241K | Sell |
3,245
-510
| -14% | -$35.5K | 0.04% | 574 |
|
|
2013
Q3 | $285K | Sell |
3,755
-4,391
| -54% | -$349K | 0.05% | 433 |
|
|
2013
Q2 | $652K | Buy |
+8,146
| New | +$600K | 0.14% | 192 |
|
Other funds holding VRTX
Prelude Capital Management's VRTX Position: Q1 2026 in Review
Prelude Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 463 shares — an estimated $210K sold.
Prelude Capital Management first reported a position in VRTX in Q2 2013 and held it in 40 quarters. The position peaked at $5.43M in Q2 2018. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Prelude Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Prelude Capital Management sold 463 Vertex Pharmaceuticals shares in Q1 2026, an estimated $210K.
- Prelude Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 40 quarters.
- Prelude Capital Management's Vertex Pharmaceuticals position peaked at $5.43M in Q2 2018.
- 1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.